Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.

Kouiavskaia DV, Dragunsky EM, Liu HM, Oberste MS, Collett MS, Chumakov KM.

Antivir Ther. 2011;16(7):999-1004. doi: 10.3851/IMP1838.

PMID:
22024515
2.

Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice.

Kouiavskaia D, Collett MS, Dragunsky EM, Sarafanov A, Chumakov KM.

Clin Vaccine Immunol. 2011 Aug;18(8):1387-90. doi: 10.1128/CVI.05147-11. Epub 2011 Jun 29.

3.

Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.

Neznanov N, Dragunsky EM, Chumakov KM, Neznanova L, Wek RC, Gudkov AV, Banerjee AK.

PLoS One. 2008 Apr 2;3(4):e1887. doi: 10.1371/journal.pone.0001887.

4.

Poliovirus-binding inhibition ELISA for evaluation of immune response to oral poliovirus vaccine: a possible alternative to the neutralization test.

Ivanov AP, Dragunsky EM, Ivanova OE, Rezapkin GV, Potapova SG, Chumakov KM.

Hum Vaccin. 2005 May-Jun;1(3):102-5. Epub 2005 May 5.

PMID:
17012865
5.

Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.

Dragunsky EM, Ivanov AP, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM.

J Infect Dis. 2006 Sep 15;194(6):804-7. Epub 2006 Aug 16.

PMID:
16941347
6.

1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.

Ivanov AP, Dragunsky EM, Chumakov KM.

J Infect Dis. 2006 Feb 15;193(4):598-600. Epub 2006 Jan 12.

PMID:
16425140
7.

ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines.

Ivanov AP, Dragunsky EM.

Expert Rev Vaccines. 2005 Apr;4(2):167-72. Review.

PMID:
15889990
8.

Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.

Dragunsky EM, Ivanov AP, Wells VR, Ivshina AV, Rezapkin GV, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM.

J Infect Dis. 2004 Oct 15;190(8):1404-12. Epub 2004 Sep 20.

PMID:
15378432
9.

Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.

Rezapkin GV, Fan L, Asher DM, Fibi MR, Dragunsky EM, Chumakov KM.

Virology. 1999 May 25;258(1):152-60.

10.

Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge.

Taffs RE, Chernokhvostova YV, Dragunsky EM, Nomura T, Hioki K, Beuvery EC, Fitzgerald EA, Levenbook IS, Asher DM.

J Infect Dis. 1997 Feb;175(2):441-4.

PMID:
9203668
11.

Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control.

Rezapkin GV, Norwood LP, Taffs RE, Dragunsky EM, Levenbook IS, Chumakov KM.

Virology. 1995 Aug 20;211(2):377-84.

12.

Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions.

Taffs RE, Chumakov KM, Rezapkin GV, Lu Z, Douthitt M, Dragunsky EM, Levenbook IS.

Virology. 1995 Jun 1;209(2):366-73.

13.

Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine.

Rezapkin GV, Chumakov KM, Lu Z, Ran Y, Dragunsky EM, Levenbook IS.

Virology. 1994 Jul;202(1):370-8.

PMID:
8009849
14.

Consistent selection of mutations in the 5'-untranslated region of oral poliovirus vaccine upon passaging in vitro.

Chumakov KM, Dragunsky EM, Norwood LP, Douthitt MP, Ran Y, Taffs RE, Ridge J, Levenbook IS.

J Med Virol. 1994 Jan;42(1):79-85.

PMID:
8308524
15.

RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence.

Chumakov KM, Norwood LP, Parker ML, Dragunsky EM, Ran YX, Levenbook IS.

J Virol. 1992 Feb;66(2):966-70.

16.

Experimental evaluation of antitoxic protective effect of new cholera vaccines in mice.

Dragunsky EM, Rivera E, Aaronson W, Dolgaya TM, Hochstein HD, Habig WH, Levenbook IS.

Vaccine. 1992;10(11):735-6.

PMID:
1441727
17.

In vitro characterization of Salmonella typhi mutant strains for live oral vaccines.

Dragunsky EM, Rivera E, Hochstein HD, Levenbook IS.

Vaccine. 1990 Jun;8(3):263-8.

PMID:
2363303
18.

Salmonella typhi vaccine strain in vitro; low infectivity in human cell line U937.

Dragunsky EM, Wooden CR, Vargo SA, Levenbook IS.

J Biol Stand. 1989 Oct;17(4):353-60.

PMID:
2613709

Supplemental Content

Loading ...
Support Center